Unicycive Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Significant Agreements (Details)

Significant Agreements (Details) - USD ($) $ in Thousands									1 Months Ended			9 Months Ended			12 Months Ended
Significant Agreements (Details) - USD ($) $ in Thousands	Apr. 10, 2023	Mar. 31, 2023	Feb. 28, 2023	Feb. 01, 2023	Aug. 31, 2022	Jul. 14, 2022	Jan. 06, 2022	Jul. 13, 2021	Jul. 27, 2022	Jul. 19, 2021	Sep. 30, 2018	Sep. 30, 2023	Sep. 29, 2023	Sep. 30, 2021	Dec. 31, 2022	Sep. 30, 2022
Significant Agreements [Line Items]
License agreement, description												No payments were made upon execution of the agreement but payments of $50,000 will be due commencing with the initiation by the Company of a second clinical trial and $50,000 on completion of such trial. At the time the FDA accepts a NDA application submitted by the Company for the product, the Company will pay Sphaera $1.65 million. Upon commercialization and sale of the drug product, royalty payments will also be payable quarterly to Sphaera equal to 2% of net sales in the preceding quarter.
Public market capitalization								$ 50,000
Anti-dilution shares of common stock (in Shares)								438,374
Services amount	$ 1,300													$ 2,200
Sublicense income percentage												40.00%
Spectrum agreement percentage															20.00%
Revisions reduced overall budget							$ 3,200
Prepaid expenses												$ 900
Remaining services budget																$ 100
Related payments												1,800
Agreements expense												1,300
Expense												600
Received upfront payment				$ 700
Future milestone payments				$ 3,700
Agreement payments												$ 2,000
Maximum [Member]
Significant Agreements [Line Items]
Tiered royalties percentage						10.00%
Shilpa Medicare Ltd [Member]
Significant Agreements [Line Items]
Company agreement description												According to the terms of the agreement Unicycive will pay the vendor $2 million in the first calendar year when the net revenue reaches $10 million from sales of Oxylanthanum Carbonate following its approval by the FDA and commercial supply of the product by the vendor (First Payment). Thereafter, the Company will pay $2 million per year for four consecutive years, after the first year’s payment, for the total payments of $10 million, provided all commercial supplies are continued to be manufactured and supplied by the vendor.
Agreements [Member]
Significant Agreements [Line Items]
Upfront payment amount					$ 1,000
Agreement payments												$ 2,000
Lotus International Pte Ltd [Member]
Significant Agreements [Line Items]
Sublicense income percentage												20.00%
Syneos Health LLC [Member]
Significant Agreements [Line Items]
Services amount										$ 2,300
Quotient Sciences Limited [Member]
Significant Agreements [Line Items]
Services amount							$ 3,700
Research related payments												$ 2,300
Prepaid expenses												1,400
Spectrum Pharmaceuticals, Inc. [Member]
Significant Agreements [Line Items]
Company issued shares (in Shares)											313,663
Common stock valued											$ 4,000
Public market capitalization											$ 50,000
Spectrum Pharmaceuticals, Inc. [Member] \| Investment [Member]
Significant Agreements [Line Items]
Interest on ownership											4.00%
Altair Nanomaterials, Inc [Member]
Significant Agreements [Line Items]
Required to pay												200
Altair [Member]
Significant Agreements [Line Items]
Required to pay												$ 4,500
Oxylanthanum Carbonate [Member]
Significant Agreements [Line Items]
Services amount													$ 1,300
Sublicense income percentage												20.00%
Research related payments									$ 2,700
Prepaid expenses									$ 2,700
Lotus International Pte Ltd [Member]
Significant Agreements [Line Items]
Research related payments			$ 700
CBCC Global Research Inc [Member]
Significant Agreements [Line Items]
Services amount												$ 1,400
Research related payments		$ 400
Related expense		$ 400
Lee’s Pharmaceutical (HK) Limited [Member]
Significant Agreements [Line Items]
Services amount						$ 1,000
Research related payments						$ 1,000
Lee’s Pharmaceutical (HK) Limited [Member] \| Minimum [Member]
Significant Agreements [Line Items]
Tiered royalties percentage						7.00%